- Home
- HSDT vs RNA Comparison
HSDT vs RNA Comparison
Compare HSDT & RNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSDT | RNA |
|---|---|---|
| Founded | N/A | 2025 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 155.6M | 141.3M |
| IPO Year | 2014 | 2025 |
Fundamental Metrics
Financial Performance| Metric | HSDT | RNA |
|---|---|---|
| Price | $2.21 | $8.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $3.50 | ★ $23.00 |
| AVG Volume (30 Days) | ★ 480.6K | 205.4K |
| Earning Date | 11-17-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 57.27 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,017,000.00 | N/A |
| Revenue This Year | $103.59 | $88.07 |
| Revenue Next Year | $13.06 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1057.12 | N/A |
| 52 Week Low | $1.19 | $7.49 |
| 52 Week High | $6.85 | $73.06 |
Technical Indicators
Market Signals| Indicator | HSDT | RNA |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 39.37 |
| Support Level | $2.11 | $7.56 |
| Resistance Level | $2.37 | $8.50 |
| Average True Range (ATR) | 0.13 | 0.35 |
| MACD | -0.03 | 0.17 |
| Stochastic Oscillator | 10.71 | 54.46 |
Price Performance
Historical ComparisonAbout HSDT Helius Medical Technologies Inc. (DE)
Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities.
About RNA Avidity Biosciences Inc.
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.